<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000607</url>
  </required_header>
  <id_info>
    <org_study_id>2018-11</org_study_id>
    <nct_id>NCT04000607</nct_id>
  </id_info>
  <brief_title>Exploratory Study of the Edwards Transcatheter Atrial Shunt System (ALt FLOW CANADA)</brief_title>
  <official_title>Exploratory Study of the Edwards Transcatheter Atrial Shunt System (ALt FLOW CANADA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Exploratory study of the Edwards Transcatheter Atrial Shunt System is a multi-center,&#xD;
      prospective, exploratory study to evaluate initial clinical safety, device functionality, and&#xD;
      effectiveness of the Edwards Transcatheter Atrial Shunt System.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of major adverse cardiac, cerebrovascular, renal events (MACCRE) and re-intervention for study device related complications at 30 days.</measure>
    <time_frame>30 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>Day 0</time_frame>
    <description>Device is deployed as intended and the delivery system is successfully removed as intended at the time of the patient's exit from the implant procedure room.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>10 Days post-op</time_frame>
    <description>Device success with evidence of shunt patency and hospital discharge without the need for additional surgical or percutaneous intervention related to the study device including unacceptable Qp/Qs values.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>30 Days</time_frame>
    <description>Procedural success without major adverse cardiac, cerebrovascular, and renal events (MACCRE) or re-intervention for study device related complications at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance/Effectiveness</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Comparison vs baseline of Qp/Qs value at 3 &amp; 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance/Effectiveness</measure>
    <time_frame>Baseline, 3 months, 6 months</time_frame>
    <description>Improvement vs baseline of PCWP at 3 &amp; 6 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Edwards Transcatheter Atrial Shunt System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Atrial Shunt</intervention_name>
    <description>Transcatheter treatment of symptomatic left heart failure patients</description>
    <arm_group_label>Edwards Transcatheter Atrial Shunt System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed and dated approved informed consent form prior to study related procedures&#xD;
&#xD;
          2. Eighteen years of age or older&#xD;
&#xD;
          3. Chronic symptomatic Heart Failure (HF) documented by the following:&#xD;
&#xD;
               1. NYHA class II with a history of NYHA class III or greater; NYHA class III, OR&#xD;
                  ambulatory NYHA class IV within last 12 months AND&#xD;
&#xD;
               2. ≥ 1 HF hospital admission (with HF as the primary, or secondary diagnosis); OR&#xD;
                  treatment with intravenous (IV) or intensification of oral diuresis for HF in a&#xD;
                  healthcare facility (emergency department/acute care facility) within the 12&#xD;
                  months prior to study entry&#xD;
&#xD;
          4. In the judgment of the investigator, subject is on stable Guideline Directed Medical&#xD;
             Therapy (GDMT) for heart failure and management of potential comorbidities according&#xD;
             to current ACCF/AHA Guidelines and that is expected to be maintained without change&#xD;
             for 3 months&#xD;
&#xD;
          5. Elevated LA (or PCWP) pressure of &gt; 15 mmHg at rest or &gt; 25 mmHg during supine&#xD;
             ergometer exercise stress test as measured at end-expiration; AND the LA (or PCWP)&#xD;
             exceeds right atrial pressure (RAP) by &gt; 5 mmHg at rest or &gt; 10 mmHg during supine&#xD;
             ergometer exercise stress test as measured at end-expiration&#xD;
&#xD;
          6. Willing to attend study follow-up assessments for up to 3 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe heart failure defined as one or more of the below:&#xD;
&#xD;
               1. ACC/AHA/ESC Stage D heart failure, non-ambulatory NYHA Class IV HF&#xD;
&#xD;
               2. If BMI &lt; 30, Cardiac index &lt; 2.0 L/min/m2&#xD;
&#xD;
               3. If BMI ≥ 30, Cardiac index &lt; 1.8 L/min/m2&#xD;
&#xD;
               4. Inotropic infusion (continuous or intermittent) within the past 6 months&#xD;
&#xD;
               5. Patient is on the cardiac transplant waiting list&#xD;
&#xD;
               6. LVEF &lt; 20%&#xD;
&#xD;
          2. Presence of significant valve disease defined by the site cardiologist as:&#xD;
&#xD;
               1. Mitral valve regurgitation defined as grade &gt; 3+ MR or &gt; moderate MS&#xD;
&#xD;
               2. Tricuspid valve regurgitation defined as grade &gt; 2+ TR&#xD;
&#xD;
               3. Aortic valve disease defined as &gt; 2+ AR or &gt; moderate AS&#xD;
&#xD;
          3. MI and/or any therapeutic invasive cardiac procedure within past 3 months; or current&#xD;
             indication for coronary revascularization;&#xD;
&#xD;
          4. Valve replacement or surgical annuloplasty within the past 12 months&#xD;
&#xD;
          5. Cardiac Resynchronization Therapy initiated, stroke or transient ischemic attack (TIA)&#xD;
             within the past 6 months&#xD;
&#xD;
          6. Hemodynamic instability within 30 days of scheduled implant procedure&#xD;
&#xD;
          7. Patient requiring surgery under general anesthesia for any reason within 30 days of&#xD;
             scheduled implant procedure&#xD;
&#xD;
          8. Clinically diagnosed hypertrophic obstructive cardiomyopathy, constrictive&#xD;
             pericarditis or other infiltrative cardiomyopathy (eg, hemochromatosis, sarcoidosis)&#xD;
&#xD;
          9. Has renal insufficiency as determined by creatinine (S-Cr) level &gt; 220 micrmol/L or&#xD;
             estimated-GFR &lt;25ml/min/1.73 m2 by CKD-Epi equation; or currently requiring dialysis&#xD;
&#xD;
         10. Significant hepatic impairment defined as 3× upper limit of normal of transaminases,&#xD;
             total bilirubin, or alkaline phosphatase&#xD;
&#xD;
         11. Right ventricular dysfunction, defined by the site cardiologist as:&#xD;
&#xD;
               1. More than mild RV dysfunction as estimated by TTE; OR&#xD;
&#xD;
               2. TAPSE &lt;1.4 cm; OR&#xD;
&#xD;
               3. RV size ≥ LV size as estimated by TTE; OR&#xD;
&#xD;
               4. Echocardiographic or clinical evidence of congestive hepatopathy;&#xD;
&#xD;
         12. Evidence of pulmonary hypertension with PVR &gt;4 Wood units&#xD;
&#xD;
         13. Performance of the 6 minute walk test with a distance &lt;50m OR &gt;400m&#xD;
&#xD;
         14. Subject is contraindicated to receive either dual antiplatelet therapy or warfarin&#xD;
             (analogue); or has a documented coagulopathy.&#xD;
&#xD;
         15. Known hypersensitivity to anticoagulation therapy or contrast agent, which cannot be&#xD;
             adequately medicated&#xD;
&#xD;
         16. Known hypersensitivity to Nickel&#xD;
&#xD;
         17. In the judgment of the investigator, life expectancy &lt;12 months for noncardiovascular&#xD;
             reasons&#xD;
&#xD;
         18. In the opinion of the investigator, the subject is not an appropriate candidate for&#xD;
             the study&#xD;
&#xD;
         19. Anatomy (including implantable devices) that is not compatible with the Edwards&#xD;
             Transcatheter Atrial Shunt System&#xD;
&#xD;
         20. Active endocarditis or infection within 3 months of scheduled implant procedure&#xD;
&#xD;
         21. Currently participating (e.g. undergoing trial specific exams/treatment/ procedures)&#xD;
             in an investigational drug or device study. Note: trials requiring extended follow-up&#xD;
             for products that were investigational but have since become commercially available&#xD;
             are not considered investigational trials.&#xD;
&#xD;
         22. History of intravenous drug use in the last 12 months&#xD;
&#xD;
         23. Positive serum pregnancy test in female subjects of child-bearing potential or nursing&#xD;
             mothers or planning on becoming pregnant during the duration of the trial&#xD;
&#xD;
         24. Patient is under guardianship&#xD;
&#xD;
         25. Known pre-existing shunting, determined to be clinically significant by the&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Melissa Arteaga</last_name>
    <phone>949-250-2002</phone>
    <email>Melissa_Arteaga@edwards.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana Gonzalez</last_name>
    <phone>949-250-4419</phone>
    <email>Ana_L_Gonzalez@edwards.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naomi Uchida</last_name>
      <phone>604-875-4521</phone>
      <email>naomi.uchida@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Jacqueline Saw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Feagan</last_name>
      <phone>613-696-7000</phone>
      <phone_ext>12678</phone_ext>
      <email>hfeagan@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Benjamin Hibbert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

